Treatment - Page 31 of 471 Posts on Medivizor
Navigation Menu

Treatment Posts on Medivizor

Daratumumab maintenance therapy after autologous stem-cell transplant in patients with newly diagnosed multiple myeloma.

Daratumumab maintenance therapy after autologous stem-cell transplant in patients with newly diagnosed multiple myeloma.

Posted by on Nov 21, 2021 in Multiple Myeloma | 0 comments

In a nutshell This study investigated the use of daratumumab (Darzalex) as maintenance therapy following autologous stem-cell transplant (ASCT) in patients with newly diagnosed multiple myeloma (NDMM). The data showed that maintenance therapy with daratumumab resulted in significant improvements in outcomes compared to observation only in patients that...

Read More

Is radiotherapy useful for the treatment of advanced Hodgkin lymphoma with bulky sites previously exposed to ABVD?

Is radiotherapy useful for the treatment of advanced Hodgkin lymphoma with bulky sites previously exposed to ABVD?

Posted by on Nov 14, 2021 in Hodgkin's lymphoma | 0 comments

In a nutshell This study investigated the potential benefits of radiotherapy (RT) for the treatment of patients with advanced-stage Hodgkin lymphoma (HL) who have achieved a complete metabolic response (CMR) after ABVD (doxorubicin, bleomycin, vinblastine, dacarbazine)-based chemotherapy. The data showed no significant difference in patient outcomes...

Read More

Evaluating the use of very low dose radiation treatment for painless non-Hodgkin lymphoma

Evaluating the use of very low dose radiation treatment for painless non-Hodgkin lymphoma

Posted by on Nov 14, 2021 in Non-Hodgkin lymphoma | 0 comments

In a nutshell The study aimed to investigate if very low-dose radiotherapy (VLDRT) was effective in treating patients with indolent (painless) non-Hodgkin lymphoma (NHL).   This study concluded that this treatment can be effective in these patients.   Some background Radiotherapy (RT) is an important treatment in managing patients...

Read More

Evaluating the effectiveness and safety of T-VEC plus surgery for the treatment of patients with resectable advanced stage melanoma.

Evaluating the effectiveness and safety of T-VEC plus surgery for the treatment of patients with resectable advanced stage melanoma.

Posted by on Nov 14, 2021 in Melanoma | 0 comments

In a nutshell This study compared the effectiveness and safety of talimogene laherparepvec (Imlygic; T-VEC) plus surgery versus surgery alone for the treatment of patients with resectable advanced stage (III or IV) melanoma. The data showed that T-VEC plus surgery was safe and effective for these patients. Some background Melanoma is an aggressive...

Read More

Evaluating the effectiveness and safety of fixed-duration treatment with ibrutinib plus venetoclax for patients with chronic lymphocytic leukemia.

Evaluating the effectiveness and safety of fixed-duration treatment with ibrutinib plus venetoclax for patients with chronic lymphocytic leukemia.

Posted by on Nov 14, 2021 in Leukemia | 0 comments

In a nutshell This study investigated the effectiveness and safety of fixed-duration treatment with ibrutinib (Imbruvica) plus venetoclax (Venclexta) for patients with previously untreated chronic lymphocytic leukemia (CLL) by using minimal residual disease (MRD) guidance. The data showed that fixed-duration treatment with ibrutinib plus venetoclax was...

Read More

Comparing outcomes after robot‑assisted and laparoscopic prostate surgery for patients with localized prostate cancer with a large prostate volume.

Comparing outcomes after robot‑assisted and laparoscopic prostate surgery for patients with localized prostate cancer with a large prostate volume.

Posted by on Nov 14, 2021 in Prostate cancer | 0 comments

In a nutshell This study compared the surgical, functional, and oncological outcomes of robotic-assisted radical prostatectomy (RARP) with standard laparoscopic radical prostatectomy (LRP) for the treatment of patients with localized prostate cancer (PCa) with a large prostate volume. The study found that RARP was associated with better surgical,...

Read More

Combining brentuximab vedotin and bendamustine for the treatment of children with relapsed/refractory Hodgkin Lymphoma

Combining brentuximab vedotin and bendamustine for the treatment of children with relapsed/refractory Hodgkin Lymphoma

Posted by on Nov 7, 2021 in Hodgkin's lymphoma | 0 comments

In a nutshell This study aimed to evaluate brentuximab vedotin (BV; Adcedris) and bendamustine (Treanda) treatment in pediatric patients with relapsed/refractory (r/r) Hodgkin Lymphoma (HL).  This study concluded that this treatment combination was safe and effective in these patients.   Some background HL is a common cancer...

Read More

Evaluating the long-term benefits and risks of trastuzumab plus chemotherapy in patients with early-stage HER2+ breast cancer.

Evaluating the long-term benefits and risks of trastuzumab plus chemotherapy in patients with early-stage HER2+ breast cancer.

Posted by on Nov 7, 2021 in Breast cancer | 0 comments

In a nutshell This study evaluated the long-term benefits and risks of trastuzumab (Herceptin) plus chemotherapy in patients with early-stage HER2-positive (+) breast cancer (BC). The data showed that trastuzumab added to chemotherapy reduced the risk of BC recurrence and death for these patients. Some background BC is classified into different...

Read More

Evaluating the cardiovascular side effects in patients with chronic lymphocytic leukemia who received acalabrutinib.

Evaluating the cardiovascular side effects in patients with chronic lymphocytic leukemia who received acalabrutinib.

Posted by on Nov 7, 2021 in Leukemia | 0 comments

In a nutshell This study evaluated the cardiovascular (CV; heart and blood vessels) side effects in patients with chronic lymphocytic leukemia (CLL) who received acalabrutinib (Calquence) treatment. The data showed that the occurrence of CV side effects with acalabrutinib treatment is very low in patients with CLL. Some background CLL is a type of...

Read More

Evaluating the effectiveness and safety of apalutamide plus abiraterone and prednisone for the treatment of patients with metastatic castration-resistant prostate cancer.

Evaluating the effectiveness and safety of apalutamide plus abiraterone and prednisone for the treatment of patients with metastatic castration-resistant prostate cancer.

Posted by on Nov 7, 2021 in Prostate cancer | 0 comments

In a nutshell This study evaluated the effectiveness and safety of apalutamide (Erleada) in combination with abiraterone acetate (Zytiga) plus prednisone (Deltasone) (AAP) for the treatment of patients with metastatic castration-resistant prostate cancer (mCRPC). The data showed that apalutamide plus AAP combination significantly improved...

Read More